Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CYW 628

Drug Profile

CYW 628

Alternative Names: CYW-628; CYWC-628

Latest Information Update: 24 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FibroBiologics
  • Class Fibroblast cell therapies; Foot disorder therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetic foot ulcer

Most Recent Events

  • 22 Apr 2024 Preclinical trials in Diabetic foot ulcers in USA (Parenteral) (Fibrobiologics pipeline, April 2024)
  • 22 Apr 2024 Fibrobiologics intends to submit an IND application for phase I/II trial to the US FDA for Diabetics foot ulcer as early as 2024 (Fibrobiologics pipeline, April 2024)
  • 16 Mar 2023 Fibrobiologics has patents pending for the Therapeutic use of fibroblasts for use in wound healing in the US, Japan, Australia, Europe and the World
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top